StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Amgen (AMGN) Announces ABP 501 Phase 3 Met Primary Endpoint in RA vs Adalimumab
November 9, 2015 5:31 PM
Amgen (NASDAQ: AMGN) presented detailed findings from a head-to-head Phase 3 study comparing the safety, efficacy and immunogenicity of biosimilar ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab
November 9, 2015 5:30 PM
Cytokinetics (CYTK) and Amgen Inc. (AMGN) Announce COSMIC-HF Data; Roth Capital Raises Price Target to $22
November 9, 2015 7:32 AM
Amgen (AMGN), Cytokinetics (CYTK) Announce COSMIC-HF Met Primary Endpoint
November 9, 2015 6:16 AM
